schwaintager.bsky.social

@schwaintager.bsky.social

TxID | AI & Cats Blending infectious diseases, machine learning, and transplant care—with a side of feline wisdom.

Congrats to my colleagues for this interesting analysis. Looking at patients who met DOTS criteria and receive dalbavancin in our hospital, they differ from the DOTS trial Younger, more IDU, more R-sided IE (less SSTI), and more persistent bacteremia. Yet, outcomes similar #IDSky

JAMA Network Open@jamanetworkopen.com · 3mo ago

In clinical practice, patients with #Bacteremia receiving dalbavancin were younger and more likely to have substance use or housing instability than those in the DOTS trial, but completed therapy with similar low failure rates. ja.ma/4odctAk

Table 2. Cohort Outcomes Comparisons. DOTS trial (n=100) shows 80% overall clinical success at day 70 & 73% composite efficacy, vs. clinical dalbavancin recipients (n=31) with 65% and 61% respectively.

The NIH can’t award ANY grants to outside researchers under new WH restriction, reports @wsj.com. The pause came in the form of a footnote from OMB Director Vought, in a document that doles out federal funds to the NIH. Prelude to rescissions, especially after his comments over the weekend?

Trump Administration Puts New Chokehold on Billions in Health-Research Funding

The National Institutes of Health can’t award grants to outside researchers under a new White House restriction.

wsj.com